William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...
“With EPKINLY ® (epcoritamab) moving from strength to strength and two wholly owned assets, rinatabart sesutecan (Rina-Sâ„¢) and acasunlimab in Phase 3 development, we are confident in the potential of ...
CEO Jan van de Winkel added, “With EPKINLY moving from strength to strength and two wholly owned assets, rinatabart sesutecan and acasunlimab in Phase 3 development, we are confident in the ...
“With EPKINLY® (epcoritamab) moving from strength to strength and two wholly owned assets, rinatabart sesutecan (Rina-Sâ„¢) and acasunlimab in Phase 3 development, we are confident in the ...
With a portfolio of marketed products, including EPKINLY, TEPKINLY, and Tivdak, and a robust pipeline featuring Epcoritamab and tisotumab vedotin, it’s advancing groundbreaking treatments in ...
Most products closed the year strong with Darzalex royalties leading the way. Epkinly net sales were $78 million, and this was slightly lower than expected due to one-time adjustments in France ...
The landing page revealed the As Ever logo, which PEOPLE understands is a tribute to Prince Harry. The logo incorporates a palm tree as a nod to the Duke and Duchess’s home in California ...
Meghan Markle recently unveiled her rebranded lifestyle brand, As Ever, and its new logo is packed with subtle nods to her family and personal history. The design features a palm tree encased by ...